Trump Announces First Industry Deal with Regeneron to Cut Drug Prices

President Trump has finalized a deal with Regeneron, marking the first of multiple planned agreements to lower drug costs. This move includes price reductions for Medicaid and a new FDA-approved drug, Otarmeni, and signals a strategic shift in drug price regulation. Future negotiations are expected to continue aiming for broader healthcare affordability.